We're getting some big news today.
That's when GW Pharmaceuticals Plc. (Nasdaq: GWPH), one of the legal marijuana stocks we follow here, is reporting its first-quarter 2018 results.
GW Pharma's share price is up 211.3% in the last two years, more than quadruple the performance of the S&P 500 over the same stretch.
Now, GW has disappointed over the past few quarters. In fact, the company posted an earnings-per-share loss of $2.08 for third-quarter 2017. That was 29% below the consensus of the seven analysts who follow it. And Wall Street punished it to the tune of 7% the day those results were released.
And we can expect to see a similar dip if GW again misses expectations on Monday. And if it does, you should see it as an opportunity to buy on the dip and get it at a discount.
That's because we're invested here for the long haul - not quarter-to-quarter results - as GW works to get its cannabis-based prescription drugs in American pharmacies.
When it comes to those marijuana-based drugs - and all the profits and share-price gains they'll soon deliver - there's a date that's much more important to us than Feb. 5.
And it's approaching fast...
In today's issue, we're talking about how its upcoming earnings report could affect GW Pharmaceuticals Inc. After all, it's "earnings season" - and dozens of S&P 500 companies are making major announcements over the next several weeks. Over and over again, announcements like these send shockwaves throughout the market and set off what can only be described as a massive price eruption.
That's why I want to introduce you to my colleague Chris Johnson. Chris is one of the specialists here at Money Map Press -and he's got a stunning new tool that gives 48-hour advanced notice of these kinds of price eruptions 100% of the time. I simply cannot deny how powerful this tool is.
Chris' Stock Market Seismograph allows him to predict massive stock-price eruptions as early as two days before they happen with 100% certainty. And these price eruptions can generate gains like 197.62%... 200%... even 223.62% - in seven trading days or less. Chris is already predicting new records for a dozen more stocks that you can take to the bank. But time is of the essence.
All the details are here. I urge you to see this in action, step by step. The potential money here is crazy big. And there's little time to waste.
On the Fast Track
GW Pharma is a UK-based biotech firm that manufactures pain drugs using compounds in cannabis.
GW has developed Sativex, a multiple sclerosis treatment available outside the United States. That gave a great head start in the race to build drug franchises around the healing powers of cannabis.
But we're much more interested in GW's other drug: Epidiolex, a cannabinoid-based drug that's aimed at treating children with severe epilepsy.
I've long predicted that Epidiolex would be approved by the U.S. Food and Drug Administration by the end of summer 2017. However, GW wasn't able to fully submit all the needed paperwork to the FDA until October.
But my prediction wasn't wrong there - it was just early.
GW has since got that paperwork in. And because the FDA had already given Epidiolex "fast-track status," it's likely to get approved soon.
The FDA grants fast-track status to drugs that show early promise for conditions that do not have approved treatment options, in an effort to get drugs approved more quickly. (Epidiolex treats four conditions that don't have adequate treatment options available: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.)
Here's how soon - and what that could mean for your shares...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
All Eyes on June 27
We recently got word that the FDA has given itself a June 27 deadline to decide whether to approve Epidiolex.
If approved, it would be the first marijuana plant-based prescription medicine approved for use in the United States. People with conditions ranging from epilepsy to severe pain to nausea have been waiting years - decades - for the FDA to make this move.
Here's what else will happen if the FDA approves Epidiolex: Your shares of GW Pharmaceuticals will start moving up, up, up.
As we always say: When laws pass - or when drugs get approved - stocks soar.
And Epidiolex's chance of getting that FDA approval skyrocketed on Feb. 24. That's when The Lancet, the highly respected medical journal, published a study that's absolutely bullish on GW's treatment.
In the study, researchers gave either Epidiolex or a placebo to more than 170 people with a rare and severe form of epilepsy. The placebo sliced the number of seizures a person experienced each month by 14%.
Epidiolex's success rate was 41%.
So GW and its investors are definitely looking forward to June 27...
Where GW Is Headed
We're not the only ones bullish on GWPH stock.
The seven analysts that follow GW Pharmaceuticals have a consensus one-year price target of $154. That gives us a potential gain of 10% over its recent trading price of $139.62.
That target is garbage.
I believe GW's headed to $208 in just the next 12 months - which would give us a 49% gain from current prices... and a 151% gain from when I first showed it to members of my Nova-X Report service.
That's where I and my members follow "pot stocks" both tiny and large each and every week. (To join us, just click here.)
Once Epidiolex hits the market and starts racking up profits, there's basically no limit to where it could go.
Now, GW is just one of the dozens of small and fast-growing legal marijuana stocks I've shown to my Nova-X members. In fact, I've put together a 90-page "bible of weed investing" so you can profit from the wave of states and nations legalizing marijuana.
In that "bible," I've shown my members stocks that have gone on to gain 175.9%... 226.7%... 763.7%... and 1516.7%. And they haven't stopped gaining yet. To find out how to get that report, click here.
Meanwhile, I'll be back soon with one of the best ways to cash in on the new tax cuts - and a way to make huge gains on Bitcoin and other cryptocurrencies that I haven't seen absolutely no one else talking about. I don't want this to be a "secret" play anymore.
The road to wealth is paved by tech, and Michael's Strategic Tech Investor puts you on the fast track to investing success with analysis, stock picks, and strategies that can double, triple – even quadruple your money quicker than any other sector on earth. Just click here to get started – it's absolutely free.
The post GW Reports Earnings Monday, but There's a Much More Profitable Date in Its Near Future appeared first on Strategic Tech Investor.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.